Unlock instant, AI-driven research and patent intelligence for your innovation.

Polypeptide for targeted inhibition of MLKL acetylation and/or derivative thereof and application thereof

A technology of acetylation and derivatives, which is applied in the field of peptides and/or derivatives that target the inhibition of MLKL acetylation, to achieve significant curative effect, less toxic and side effects, and promote lung regeneration

Pending Publication Date: 2022-04-29
THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the study of KAT5 in pulmonary fibrosis has not been reported yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide for targeted inhibition of MLKL acetylation and/or derivative thereof and application thereof
  • Polypeptide for targeted inhibition of MLKL acetylation and/or derivative thereof and application thereof
  • Polypeptide for targeted inhibition of MLKL acetylation and/or derivative thereof and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Preparation of an animal model of pulmonary fibrosis

[0034] 1.1 Main reagents and experimental animals

[0035] The bleomycin used in the experiment was purchased from Nippon Kayaku, lot number X81040.

[0036]The compounds used in the experiments were purchased from Sigma unless otherwise specified.

[0037] The SPF grade C57BL / 6 mice (male, 6-8 weeks old, 16-18 g) used in the experiment were purchased from Hunan Slack Jingda Experimental Animal Co., Ltd.

[0038] 1.2 Preparation of animal model of pulmonary fibrosis

[0039] Male C57BL / 6 (age 6-8 weeks) mice were fasted overnight, anesthetized with sodium pentobarbital (45mg / kg, i.p.), and injected with bleomycin (1U / kg) intratracheally for a total of 6 days. times, each interval is 14 days.

[0040] The specific plan is: fix the mouse in the prone position after anesthesia, irradiate the neck of the mouse with a cold light source, pull the mouse tongue out with the tweezers in the right hand, and open...

Embodiment 2

[0041] Example 2 Real-time fluorescence quantitative PCR method detects the expression of KAT5 in the lung tissue of mice with pulmonary fibrosis

[0042] 1. Isolate the lung tissue of mice in the normal group and the model group, and extract RNA. Total tissue RNA was extracted by Trizol method, the steps are as follows:

[0043] (1) Weigh the tissue, cut it into small pieces, and place it in a 1.5mL EP tube.

[0044] (2) Add 1 mL of Trizol solution, mix well, and use a tissue homogenizer to fully grind the tissue and lyse the lysed cells.

[0045] (3) Add 200 μL of chloroform to the lysate, vortex thoroughly for 30 seconds, and then let stand at room temperature for 15 minutes.

[0046] (4) Centrifuge at 12,000×g at 4°C for 15 minutes, and pipette 400 μL of the upper colorless aqueous phase into a new EP tube.

[0047] (5) Add 400 μL of isopropanol, turn it upside down, and let stand at room temperature for 10 minutes.

[0048] (6) Centrifuge at 12,000×g at 4°C for 10 min...

Embodiment 3

[0069] Example 3 Verification of the binding of KAT5 and protein MLKL in alveolar macrophages by co-immunoprecipitation

[0070] 3.1 Co-immunoprecipitation reagents

[0071] Lysis solution A: 0.6057g Tris base, 1.7532g NaCl, 0.1017g MgCl 2 ·6H 2 O, 0.0742g EDTA, 10mL glycerin, 10mL 10% NP40, add deionized water to 150mL, adjust the pH value to 7.6 with HCl, adjust the volume to 191mL, mix well, filter through a 0.45μm membrane filter, and store at 4°C.

[0072] Lysis Solution B: 200μL 2M β-glycerophosphate, 4mL 2.5M NaF, 2mL 100mM NaVO 3 , 2mL 100mMPMSF, 20μL 1M DTT, 200μL each of 1mg / mL Leu, Pep, and Apr, the total volume is 9mL. The mother liquor was stored at -20°C. Before use, thaw the mother liquor of each component in liquid B, add it to liquid A according to the above composition ratio and mix well.

[0073] Protein A / G Plus-Agarose was purchased from Santa Cruz, USA.

[0074] 3.2 Specific operation steps

[0075] (1) Collect alveolar macrophages in mouse alveola...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicines, and discloses a polypeptide and / or a polypeptide derivative thereof capable of being specifically combined with KAT5 so as to inhibit MLKL acetylation in a targeted manner, and application of the polypeptide and / or the polypeptide derivative. The amino acid sequence of the polypeptide M2 disclosed by the invention is as shown in SEQ ID NO: 1, and the polypeptide M2 can be specifically combined with KAT5, so that KAT5 acetylated MLKL protein is blocked; the invention also discloses a polypeptide derivative which is a chimeric peptide PM2 formed by combining a polypeptide M2 and a cell-penetrating peptide, the amino acid sequence of the cell-penetrating peptide is as shown in SEQ ID NO: 2, and the polypeptide and / or the polypeptide derivative thereof are / is remarkable in curative effect on pulmonary fibrosis diseases, small in toxic and side effects and safe to use.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a polypeptide and / or derivatives thereof capable of specifically binding to KAT5 to target and inhibit MLKL acetylation and applications thereof. Background technique [0002] Pulmonary fibrosis is the end-stage change of a large class of lung diseases characterized by fibroblast proliferation and accumulation of a large amount of extracellular matrix, accompanied by inflammatory damage and tissue structure destruction. A serious pathological condition. Most of its pathological changes are characterized by initial lower airway inflammation, alveolar epithelial cells and vascular endothelial cell damage, accompanied by fibroblast and type II alveolar cell proliferation, cytokine release, extracellular matrix protein and collagen deposition, and eventually lead to lung cancer. changes. The alveoli in the lungs of patients with pulmonary fibrosis are gradually replaced by fibrous subs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C07K19/00A61K38/08A61K47/64A61P11/00A61P29/00
CPCC07K7/06A61K38/08A61K47/64A61P11/00A61P29/00C07K2319/10C07K2319/33
Inventor 刘姗姗周智广肖扬李霞闵加莉李巧刘索思王倩蓉
Owner THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV